GLP-1 receptor agonists – Current Treatment – Current Treatment: Physician Insights – GLP-1 Receptor Agonist Products (US)
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) products like Novo Nordisk’s SC semaglutide (Ozempic / Wegovy) and Eli Lilly’s tirzepatide (Mounjaro / Zepbound) have seen significant growth in recent years. Physicians and patients are increasingly drawn to these therapies for their proven clinical efficacy, convenient dosing, and overall safety profiles. Prescribing decisions for GLP-1 RA products are shaped by multiple factors, including clinical trial outcomes, real-world evidence, and patient-specific considerations such as comorbidities. However, barriers such as cost and challenging reimbursement often limit broader adoption. Understanding what drives physician prescribing behavior is crucial for optimizing the use of GLP-1 RA products and addressing gaps in patient care as demand for effective metabolic therapies continues to rise.
Questions answered
- What is the perception of endocrinologists versus primary care physicians regarding the use of GLP-1 RA products for the treatment of T2D and obesity?
- Which GLP-1 RA products are most preferred vs. most prescribed among specialists for patients with T2D and/or obesity?
- What impact would the removal of barriers to prescribing GLP-1 RA products have on physicians’ prescribing behavior for other approved drugs?
- What factors influence the prescription choices of endocrinologists when prescribing a GLP-1 RA brand to T2D patients who are obese?
Content highlights
- Geography: United States
- Primary research: survey of 100 U.S. endocrinologists and primary care physicians / general practitioners
- Key drugs covered: Ozempic, Rybelsus, Saxenda, Trulicity, Wegovy, Zepbound
- Key insights provided:
- Factors influencing disease management and treatment decisions
- Drivers and constraints of drug selection
- Physician-reported treatment practices
- Physician insight on compliance
- Physician-reported recent / anticipated changes in drug usage or treatment approach
Product description
Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:
- Understand the treatment landscape for a disease and how physicians make prescribing decisions.
- Evaluate the drivers and obstacles that influence treatment selection.
- Analyze your brand’s performance from the physician perspective to enhance or defend your competitive position.
